Although osimertinib (a third-generation EGFR tyrosine kinase inhibitor (TKI)) is used as the primary treatment for EGFR-mutant NSCLC (Johnson et al., 2022), clinical observations reveal two critical limitations: heightened incidence of adverse events (AEs) with third-generation TKIs; diminished efficacy against ex20ins variants owing to conformational alterations of the kinase-active site (Riess et al., 2024; Robichaux et al., 2018b). Here, EGFR is linked to non-small cell lung carcinoma.